Literature DB >> 24128438

Estrogen response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms.

Natsu Fujiki1, Hiromi Konno, Yosuke Kaneko, Tatsuyuki Gohno, Toru Hanamura, Koshi Imami, Yasushi Ishihama, Kyoko Nakanishi, Toshifumi Niwa, Yuko Seino, Yuri Yamaguchi, Shin-ichi Hayashi.   

Abstract

The acquisition of estrogen-deprivation resistance and estrogen receptor (ER) signal-independence in ER-positive breast cancer is one of the crucial steps in advancing the aggressiveness of breast cancer; however, this has not yet been elucidated in detail. To address this issue, we established several estrogen-deprivation-resistant (EDR) breast cancer cell lines from our unique MCF-7 cells, which had been stably transfected with an ERE-GFP reporter plasmid. Three cell lines with high ER activity and another 3 cell lines with no ER activity were established from cell cloning by monitoring GFP expression in living cells. The former three ERE-GFP-positive EDR cell lines showed the overexpression of ER and high expression of several ER-target genes. Further analysis of intracellular signaling factors revealed a marked change in the phosphorylation status of ERα on Ser167 and Akt on Thr308 by similar mechanisms reported previously; however, we could not find any changes in MAP-kinase factors. Comprehensive phospho-proteomic analysis also indicated the possible contribution of the Akt pathway to the phosphorylation of ERα. On the other hand, constitutive activation of c-Jun N-terminal kinase (JNK) was observed in ERE-GFP-negative EDR cells, and the growth of these cells was inhibited by a JNK inhibitor. An IGF1R-specific inhibitor diminished the phosphorylation of JNK, which suggested that a novel signaling pathway, IGF1R-JNK, may be important for the proliferation of ER-independent MCF-7 cells. These results indicate that ER-positive breast cancer cells can acquire resistance by more than two mechanisms at a time, which suggests that multiple mechanisms may occur simultaneously. This finding also implies that breast cancers with different resistance mechanisms can concomitantly occur and mingle in an individual patient, and may be a cause of the recurrence of cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; EDR; Estrogen; Estrogen-deprivation resistance; Hormonal therapy; LTED; estrogen-deprivation-resistant; long-term estrogen-depleted

Mesh:

Substances:

Year:  2013        PMID: 24128438     DOI: 10.1016/j.jsbmb.2013.08.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.

Authors:  Xue Zeng; Xiaofang Che; Yun-Peng Liu; Xiu-Juan Qu; Lu Xu; Chen-Yang Zhao; Chun-Lei Zheng; Ke-Zuo Hou; Yuee Teng
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

2.  Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.

Authors:  Kanami Uchiumi; Kouki Tsuboi; Nozomi Sato; Takako Ito; Hisashi Hirakawa; Toshifumi Niwa; Yuri Yamaguchi; Shin-Ichi Hayashi
Journal:  Breast Cancer       Date:  2019-01-04       Impact factor: 4.239

Review 3.  Mechanisms of hormonal therapy resistance in breast cancer.

Authors:  Shin-ichi Hayashi; Mariko Kimura
Journal:  Int J Clin Oncol       Date:  2015-02-05       Impact factor: 3.402

4.  Anti-apoptotic effects of PCP4/PEP19 in human breast cancer cell lines: a novel oncotarget.

Authors:  Taiji Hamada; Masakazu Souda; Takuya Yoshimura; Shoko Sasaguri; Kazuhito Hatanaka; Takashi Tasaki; Takako Yoshioka; Yasuyo Ohi; Sohsuke Yamada; Masato Tsutsui; Yoshihisa Umekita; Akihide Tanimoto
Journal:  Oncotarget       Date:  2014-08-15

5.  Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.

Authors:  Yoko Omoto; Takashi Takeshita; Yutaka Yamamoto; Mutsuko Yamamoto-Ibusuki; Mitsuhiro Hayashi; Aiko Sueta; Saori Fujiwara; Tetsuya Taguchi; Hirotaka Iwase
Journal:  Springerplus       Date:  2015-03-05

6.  Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.

Authors:  Masahiro Hikichi; Toshiaki Utsumi; Takanori Hayashi; Jun Yukitake; Toru Wakatsuki; Eiji Nishio; Nobuhiro Harada
Journal:  Oncotarget       Date:  2018-05-04

7.  The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.

Authors:  Masafumi Iida; Misato Nakamura; Emi Tokuda; Daichi Toyosawa; Toshifumi Niwa; Noriaki Ohuchi; Takanori Ishida; Shin-Ichi Hayashi
Journal:  Oncotarget       Date:  2019-08-06

8.  Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.

Authors:  Toru Higuchi; Megumi Endo; Toru Hanamura; Tatsuyuki Gohno; Toshifumi Niwa; Yuri Yamaguchi; Jun Horiguchi; Shin-Ichi Hayashi
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.

Authors:  Mariko Kimura; Toru Hanamura; Kouki Tsuboi; Yosuke Kaneko; Yuri Yamaguchi; Toshifumi Niwa; Kazutaka Narui; Itaru Endo; Shin-Ichi Hayashi
Journal:  Oncotarget       Date:  2018-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.